Octozi vs Saama (2026)
Both apply AI to clinical trial data operations, at different scales. Octozi is a younger specialist: agents for data cleaning, medical review, safety review and reconciliation, medical monitoring and clinical operations work across five modules on one workspace, harmonizing EDC, safety, laboratory, CTMS, eCOA and IRT data and drafting queries reviewers accept, edit or reject. Saama is an established platform with a wider reach. Its models draft data queries for reviewer approval, Source to Submission maps data to CDISC SDTM, Clinical AI Agents run from study start to submission, and the company reports use in more than 1,500 studies, backed by a growth investment led by Carlyle. Octozi suits a team that wants agents across the data review workflow on one workspace; Saama suits a sponsor that wants a proven platform reaching through to submission.
- Five modules on one workspace, from data cleaning to medical monitoring.
- Models fine tuned from Llama 4 paired with heuristic checks, with customer data kept out of training.
- SOC 2 Type II and separate environments for each customer.
- Data quality, SDTM mapping and agents from study start to submission.
- More than 40 connectors into a sponsor's systems.
- Scale the company reports at over 50 sponsors, with Pfizer on its data review automation since 2020.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Octozi and Saama are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Octozi | Saama |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Founded | 2024 | Not recorded |
| Headquarters | New York, New York, United States | Campbell, California |
| Website | octozi.com | saama.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
New York company applying AI agents to clinical trial data operations: data cleaning, medical data review, safety review and reconciliation, medical monitoring and clinical operations, across five modules on one workspace for the study team. It harmonizes EDC, safety, laboratory, CTMS, eCOA and IRT data with source traceability and pairs proprietary language models fine-tuned from Llama 4 with heuristic algorithms, flagging discrepancies and drafting queries that reviewers accept, edit or reject.
Source: AI Health Index, September 2026
Saama, based in Campbell, California, sells a clinical data platform and AI modules to pharmaceutical and biotechnology sponsors and contract research organizations. Smart Data Quality uses models to find data discrepancies and draft queries for reviewer approval, with a generative copilot that writes and tests data quality checks.
Source: AI Health Index, September 2026
Questions buyers ask
How are Octozi and Saama priced and sold?
For Octozi, the company's economic model of a representative phase 3 oncology trial estimates $5.1 million saved per study, mostly from a five-day-earlier database lock, which a sponsor can compare with its own delay costs; it models a representative trial rather than measuring one. Sales are to sponsors and contract research organizations by demo request.
With Saama, enterprise agreements with pharmaceutical and biotechnology sponsors and contract research organizations, sold as platform software and as customized solutions and services, with agents offered as modular additions to a sponsor's existing platforms. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How do Octozi and Saama handle patient data?
In Octozi's case, the training exclusion matters for sponsors who will not expose unblinded trial data to a vendor that might learn from it.
For Saama, the privacy notice (effective 25 Apr 2024) says the company processes pseudonymized trial participant data as a processor for sponsors and contract research organizations, keeps personal information as long as reasonably necessary or as agreed by contract, and may use anonymized data indefinitely. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Which settings and specialties do Octozi and Saama cover?
With Octozi, the platform covers the clinical trial data layer (data management, clinical science review, safety review and reconciliation, medical monitoring and clinical operations) for pharmaceutical, biotech and medtech sponsors and contract research organizations. The only published evaluation used synthetic data built from one phase 3 oncology trial.
In Saama's case, the clinical platform covers sponsor-side development from study design and startup through conduct, biometrics and submission, and the company also sells commercial, medtech and provider-side products (revenue cycle management, care coordination, hospital orchestration) that sit outside the trial scope this listing describes. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
What evidence is published for Octozi and Saama?
For Octozi, the home page cites these as an 85 percent reduction in data errors and six-fold median throughput.
With Saama, the home page credits Smart Data Quality with more than 20,000 hours of manual work saved, Patient Insights with 40 percent time savings in patient data review, and the document generator with 30 percent less drafting time. The BRAIN SDTM page says its automation is expected to cut effort by 50 percent and output generation timelines by 69 percent per study. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers.
Both records were reviewed on this site in September 2026. Neither company publishes a price. Octozi lists SOC 2 Type II; no security attestation was found on Saama's own site, and Octozi's six fold faster review comes from a preprint on synthetic data.
Ask both what share of drafted queries reviewers reject, and how that number is tracked.